NCT Number: NCT01332383
Special Drug Use Investigation for AMERGE® Tablet (Long-term)
To investigate the long-term safety and efficacy of AMERGE (naratriptan hydrochloride) on Japanese patients with migraine headache in clinical setting
Looking for future studies?
Notify MeKey information
Conditions
Sex eligibility
All sexes
Study type
Observational
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Must use AMERGE for the first time
Exclusion criteria
- Patients with hypersensitivity to naratriptan or any of the components.
- Patients with history, symptoms, or signs of myocardial infarction, ischemic cardiac or angina inversa
- Patients with history of cerebral vascular disturbance or transient ischaemic attack
- Patients with peripheral vascular syndromes
- Patients with uncontrolled hypertension
- Patients with severe renal or hepatic impairment
- Patients using treatment with another 5-HT1 agonist, an ergotamine-containing or ergot-type medication
Treatment and study plan
Primary outcomes
-
The number of adverse drug reactions and serious adverse events
Time frame: 6 months
Interested in participating?
Looking for future studies?
Notify MeSponsors and collaborators
Lead sponsor
GlaxoSmithKline
Industry
Registry information
Official study title
Special Drug Use Investigation for AMERGE Tablet (Long-term)
Important dates
- Study start
- 2009
- Primary completion
- 2013
- Study completion
- 2013
- First posted
- Apr 11, 2011
- Registry last updated
- Aug 13, 2015
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Migraine Manager (R01)
NCT04567355
Brain Diseases, Central Nervous System Diseases
Cincinnati, Ohio, United States
View Trial DetailsTai Chi for the Prophylaxis of Episodic Migraine: the Efficacy Examination and Mechanism Exploration
NCT05690737
Brain Diseases, Central Nervous System Diseases
Hong Kong, HONG KONG
View Trial DetailsVideonystagmography and Vestibular Migraine
NCT07000929
Brain Diseases, Central Nervous System Diseases
Essen, North Rhine-Westphalia, Germany
View Trial DetailsBotulinum Toxin Type A Blockade of the Sphenopalatine Ganglion in Treatment-refractory Chronic Migraine
NCT04069897
Brain Diseases, Central Nervous System Diseases
Bergen, Norway
View Trial Details